{"transactions":[{"id":737389,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-15T21:57:01.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":2700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":2700,"derivative":{"exercise_price":0.947,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":2700},"source":{"system":"sec-edgar","filing":"0000912282-26-000832","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000832/form4.xml","form_type":"4"}},{"id":737407,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-15T21:51:59.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":2700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":2700,"derivative":{"exercise_price":0.947,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":2700},"source":{"system":"sec-edgar","filing":"0000912282-26-000830","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000091228226000830/form4.xml","form_type":"4"}},{"id":741341,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":6837319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date."}],"balance_after":6837319,"derivative":{"exercise_price":0.84,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":6837319},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741340,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":6837319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":6837319,"derivative":{"exercise_price":0.84,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":6837319},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741339,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":2070107,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":2070107,"derivative":{"exercise_price":0.09,"expiration_date":"2036-03-15","underlying":"Common Stock","underlying_shares":2070107},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741338,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":133615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":133615,"derivative":{"exercise_price":0.09,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":133615},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741337,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":362092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":362092,"derivative":{"exercise_price":0.09,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":362092},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741336,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":69350,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":69350,"derivative":{"exercise_price":0.09,"expiration_date":"2033-07-30","underlying":"Common Stock","underlying_shares":69350},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741335,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":124830,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":124830,"derivative":{"exercise_price":0.09,"expiration_date":"2032-09-05","underlying":"Common Stock","underlying_shares":124830},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741334,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":228855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":228855,"derivative":{"exercise_price":0.09,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":228855},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741333,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":34675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC (\"Orphai\") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the \"Merger Agreement\"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Orphai Holdings Therapeutics, Inc., a Delaware corporation (\"HoldCo\") and Orphai."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC (\"Orphai\") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the \"Merger Agreement\"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Orphai Holdings Therapeutics, Inc., a Delaware corporation (\"HoldCo\") and Orphai."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":34675,"derivative":{"exercise_price":0.09,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":34675},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":931955,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-24T01:05:44.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":false,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029."}],"balance_after":365000,"derivative":{"exercise_price":3.08,"expiration_date":"2036-01-23","underlying":"Common Shares","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0000912282-26-000119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000119/form4.xml","form_type":"4"}},{"id":932270,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-23T20:25:04.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029."}],"balance_after":1000000,"derivative":{"exercise_price":3.08,"expiration_date":"2036-01-23","underlying":"Common Shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000912282-26-000121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228226000121/form4.xml","form_type":"4"}},{"id":931973,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-23T20:07:30.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029."}],"balance_after":200000,"derivative":{"exercise_price":3.08,"expiration_date":"2036-01-23","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000912282-26-000120","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000091228226000120/form4.xml","form_type":"4"}},{"id":934015,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-01-21T23:14:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":21810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":21810,"derivative":{"exercise_price":3,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":21810},"source":{"system":"sec-edgar","filing":"0000912282-26-000089","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000091228226000089/form4.xml","form_type":"4"}},{"id":934014,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-01-21T23:10:35.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":19547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":19547,"derivative":{"exercise_price":3,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":19547},"source":{"system":"sec-edgar","filing":"0000912282-26-000087","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000087/form4.xml","form_type":"4"}},{"id":934012,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-01-21T23:05:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":29423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":29423,"derivative":{"exercise_price":3,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":29423},"source":{"system":"sec-edgar","filing":"0000912282-26-000085","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000085/form4.xml","form_type":"4"}},{"id":934013,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-01-21T22:59:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":18724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":18724,"derivative":{"exercise_price":3,"expiration_date":"2036-01-02","underlying":"Common Shares","underlying_shares":18724},"source":{"system":"sec-edgar","filing":"0000912282-26-000083","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000083/form4.xml","form_type":"4"}},{"id":957896,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":70810,"kind":"person","name":"Benatti Luca","position":1,"cik":"0001613842","reported_name":"Benatti Luca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T17:36:12.000Z","date":"2025-12-26","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":3.47,"value":173500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":39179,"source":{"system":"sec-edgar","filing":"0000912282-25-001469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613842/000091228225001469/form4.xml","form_type":"4"}},{"id":957895,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":70810,"kind":"person","name":"Benatti Luca","position":1,"cik":"0001613842","reported_name":"Benatti Luca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T17:34:30.000Z","date":"2024-10-23","kind":"other","planned":false,"acquired":true,"shares":8918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the \"Acquisition\"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the \"Acquisition\"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024."}],"balance_after":89179,"source":{"system":"sec-edgar","filing":"0000912282-25-001468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613842/000091228225001468/form4.xml","form_type":"4"}},{"id":971159,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-12-12T17:07:23.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":true,"shares":739885,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Thye Trust"},"balance_after":739885,"source":{"system":"sec-edgar","filing":"0000912282-25-001407","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225001407/form4.xml","form_type":"4"}},{"id":971158,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-12-12T17:07:23.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":false,"shares":739885,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":255000,"source":{"system":"sec-edgar","filing":"0000912282-25-001407","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225001407/form4.xml","form_type":"4"}},{"id":977285,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":false,"shares":25280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of 225,000 employee stock options on February 2, 2023, which vest in equal monthly installments at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, with full vesting on the fourth annual anniversary of the vesting commencement date."}],"balance_after":199720,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Shares","underlying_shares":25280},"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977284,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":false,"shares":2271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of 103,500 employee stock options on May 19, 2022, which vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":45168,"derivative":{"exercise_price":0.55,"expiration_date":"2032-05-22","underlying":"Common Shares","underlying_shares":2271},"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977283,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":true,"shares":25280,"price":0.94,"value":23763.2,"ownership":{"direct":true},"balance_after":361827,"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977282,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":true,"shares":2271,"price":0.55,"value":1249.05,"ownership":{"direct":true},"balance_after":336547,"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":1103425,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"officer":true,"officer_title":"CBO, COO & CCO"}}],"security":"Warrants","published_at":"2025-06-23T12:48:00.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":37736,"price":0.125,"value":4717.0,"ownership":{"direct":true},"balance_after":37736,"derivative":{"exercise_price":1.2,"exercise_date":"2025-06-18","expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":37736},"source":{"system":"sec-edgar","filing":"0000912282-25-000697","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000697/form4.xml","form_type":"4"}},{"id":1103424,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"officer":true,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-06-23T12:48:00.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":37736,"price":1.2,"value":45283.2,"ownership":{"direct":true},"balance_after":334276,"source":{"system":"sec-edgar","filing":"0000912282-25-000697","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000697/form4.xml","form_type":"4"}},{"id":1103453,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"officer":true,"officer_title":"President"}}],"security":"Warrants","published_at":"2025-06-23T08:46:04.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":7548,"price":0.125,"value":943.5,"ownership":{"direct":true},"balance_after":7548,"derivative":{"exercise_price":1.2,"exercise_date":"2025-06-18","expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":7548},"source":{"system":"sec-edgar","filing":"0000912282-25-000696","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000091228225000696/form4.xml","form_type":"4"}},{"id":1103452,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"officer":true,"officer_title":"President"}}],"security":"Common Shares","published_at":"2025-06-23T08:46:04.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":7548,"price":1.2,"value":9057.6,"ownership":{"direct":true},"balance_after":130009,"source":{"system":"sec-edgar","filing":"0000912282-25-000696","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000091228225000696/form4.xml","form_type":"4"}},{"id":1103754,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"officer_title":"CEO and CMO"}}],"security":"Warrants","published_at":"2025-06-23T08:43:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":150944,"price":0.125,"value":18868.0,"ownership":{"direct":true},"balance_after":150944,"derivative":{"exercise_price":1.2,"exercise_date":"2025-06-18","expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":150944},"source":{"system":"sec-edgar","filing":"0000912282-25-000695","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225000695/form4.xml","form_type":"4"}},{"id":1103753,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-06-23T08:43:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":150944,"price":1.2,"value":181132.8,"ownership":{"direct":true},"balance_after":994885,"source":{"system":"sec-edgar","filing":"0000912282-25-000695","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225000695/form4.xml","form_type":"4"}},{"id":1119347,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35617,"kind":"person","name":"RYAN UNA S","position":1,"cik":"0001255349","reported_name":"RYAN UNA S","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:52:41.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000625","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255349/000091228225000625/form4.xml","form_type":"4"}},{"id":1119134,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:36:21.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000621","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000091228225000621/form4.xml","form_type":"4"}},{"id":1119127,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:33:18.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000619","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000619/form4.xml","form_type":"4"}},{"id":1119126,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:27:06.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000617","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000617/form4.xml","form_type":"4"}},{"id":1119125,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:07:25.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000613/form4.xml","form_type":"4"}},{"id":1119147,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":70810,"kind":"person","name":"Benatti Luca","position":1,"cik":"0001613842","reported_name":"Benatti Luca","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T17:38:57.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000623","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613842/000091228225000623/form4.xml","form_type":"4"}},{"id":1119145,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T17:14:19.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000091228225000615/form4.xml","form_type":"4"}},{"id":1273447,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO and CCO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-11T22:41:41.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":450000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-003613","document":"form4-02112025_100238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925003613/form4-02112025_100238.xml","form_type":"4"}},{"id":1273808,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-11T17:44:38.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":1200000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001415889-25-003618","document":"form4-02112025_100234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588925003618/form4-02112025_100234.xml","form_type":"4"}},{"id":1273471,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-11T17:43:17.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":300000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-25-003615","document":"form4-02112025_100214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000141588925003615/form4-02112025_100214.xml","form_type":"4"}},{"id":1306351,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-09T00:33:26.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":31613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":31613,"derivative":{"exercise_price":1.88,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":31613},"source":{"system":"sec-edgar","filing":"0001415889-25-001164","document":"form4-01092025_120123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925001164/form4-01092025_120123.xml","form_type":"4"}},{"id":1306350,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-09T00:32:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":30282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":30282,"derivative":{"exercise_price":1.88,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":30282},"source":{"system":"sec-edgar","filing":"0001415889-25-001163","document":"form4-01092025_120106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925001163/form4-01092025_120106.xml","form_type":"4"}},{"id":1306349,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-09T00:30:58.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":47587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":47587,"derivative":{"exercise_price":1.88,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":47587},"source":{"system":"sec-edgar","filing":"0001415889-25-001162","document":"form4-01092025_120154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925001162/form4-01092025_120154.xml","form_type":"4"}},{"id":1306359,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-09T00:29:14.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":35274,"derivative":{"exercise_price":1.88,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":35274},"source":{"system":"sec-edgar","filing":"0001415889-25-001160","document":"form4-01092025_120111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000141588925001160/form4-01092025_120111.xml","form_type":"4"}},{"id":1417726,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:38:44.000Z","date":"2024-08-30","kind":"purchase","planned":false,"acquired":true,"shares":77000,"price":0.7,"value":53900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive."}],"balance_after":843941,"source":{"system":"sec-edgar","filing":"0001415889-24-022702","document":"form4-09032024_090940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924022702/form4-09032024_090940.xml","form_type":"4"}},{"id":1417725,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:38:44.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":77500,"price":0.69,"value":53475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":766941,"source":{"system":"sec-edgar","filing":"0001415889-24-022702","document":"form4-09032024_090940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924022702/form4-09032024_090940.xml","form_type":"4"}},{"id":1424975,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Common Stock","published_at":"2024-08-22T17:51:16.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":48387,"price":0.65,"value":31451.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.62 to $0.66, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":122461,"source":{"system":"sec-edgar","filing":"0001415889-24-022054","document":"form4-08222024_090813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000141588924022054/form4-08222024_090813.xml","form_type":"4"}},{"id":1426254,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":23565,"price":0.63,"value":14845.95,"ownership":{"direct":true},"balance_after":296540,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426253,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.62,"value":3100.0,"ownership":{"direct":true},"balance_after":272975,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426252,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":2280,"price":0.61,"value":1390.8,"ownership":{"direct":true},"balance_after":267975,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426251,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":3424,"price":0.6,"value":2054.4,"ownership":{"direct":true},"balance_after":265695,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":0.61,"value":1525.0,"ownership":{"direct":true},"balance_after":262271,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426249,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-19","kind":"purchase","planned":false,"acquired":true,"shares":2155,"price":0.58,"value":1249.9,"ownership":{"direct":true},"balance_after":259771,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1486075,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T01:08:59.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016093","document":"form4-06082024_010656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924016093/form4-06082024_010656.xml","form_type":"4"}},{"id":1486074,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T01:04:19.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016092","document":"form4-06082024_010616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924016092/form4-06082024_010616.xml","form_type":"4"}},{"id":1486376,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35617,"kind":"person","name":"RYAN UNA S","position":1,"cik":"0001255349","reported_name":"RYAN UNA S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T01:03:00.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016091","document":"form4-06082024_010657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255349/000141588924016091/form4-06082024_010657.xml","form_type":"4"}},{"id":1486101,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T01:00:54.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016090","document":"form4-06082024_010651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000141588924016090/form4-06082024_010651.xml","form_type":"4"}},{"id":1486073,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T00:59:30.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016089","document":"form4-06082024_120627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924016089/form4-06082024_120627.xml","form_type":"4"}},{"id":1486123,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":70810,"kind":"person","name":"Benatti Luca","position":1,"cik":"0001613842","reported_name":"Benatti Luca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-07T20:57:22.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016088","document":"form4-06082024_120618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613842/000141588924016088/form4-06082024_120618.xml","form_type":"4"}},{"id":1486121,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-07T20:55:27.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":13500,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001415889-24-016087","document":"form4-06082024_120623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000141588924016087/form4-06082024_120623.xml","form_type":"4"}},{"id":1489390,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-05T18:37:39.000Z","date":"2024-06-04","kind":"exercise","planned":false,"acquired":false,"shares":56061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":47439,"derivative":{"exercise_price":0.55,"expiration_date":"2032-03-27","underlying":"Common Stock","underlying_shares":56061},"source":{"system":"sec-edgar","filing":"0001415889-24-015533","document":"form4-06052024_060635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924015533/form4-06052024_060635.xml","form_type":"4"}},{"id":1489389,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-06-05T18:37:39.000Z","date":"2024-06-04","kind":"exercise","planned":false,"acquired":true,"shares":56061,"price":0.55,"value":30833.55,"ownership":{"direct":true},"balance_after":257616,"source":{"system":"sec-edgar","filing":"0001415889-24-015533","document":"form4-06052024_060635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924015533/form4-06052024_060635.xml","form_type":"4"}},{"id":1640545,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-15T18:14:09.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of February 15, 2024, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date."}],"balance_after":54000,"derivative":{"exercise_price":1.3,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001415889-24-003984","document":"form4-02152024_110201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000141588924003984/form4-02152024_110201.xml","form_type":"4"}},{"id":1660682,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-02T22:53:07.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":600000,"derivative":{"exercise_price":1.31,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001415889-24-002379","document":"form4-02022024_100258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924002379/form4-02022024_100258.xml","form_type":"4"}},{"id":1660706,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-02T18:02:04.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":145000,"derivative":{"exercise_price":1.31,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001415889-24-002380","document":"form4-02022024_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000141588924002380/form4-02022024_110255.xml","form_type":"4"}},{"id":1661691,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-02T17:50:21.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":1500000,"derivative":{"exercise_price":1.31,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001415889-24-002378","document":"form4-02022024_100215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924002378/form4-02022024_100215.xml","form_type":"4"}},{"id":1677873,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":false,"shares":149999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":450001,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":149999},"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677872,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":false,"shares":90531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":115860,"derivative":{"exercise_price":0.55,"expiration_date":"2022-03-27","underlying":"Common Stock","underlying_shares":90531},"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677871,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":true,"shares":149999,"price":0.94,"value":140999.06,"ownership":{"direct":true},"balance_after":689441,"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677870,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":true,"shares":90531,"price":0.55,"value":49792.05,"ownership":{"direct":true},"balance_after":539442,"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1710594,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T23:21:33.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":22627,"price":1.04,"value":23532.08,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2347545,"source":{"system":"sec-edgar","filing":"0001209191-23-058694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123058694/doc4.xml","form_type":"4"}},{"id":1710593,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T23:21:33.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":22627,"price":1,"value":22627.0,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2324918,"source":{"system":"sec-edgar","filing":"0001209191-23-058694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123058694/doc4.xml","form_type":"4"}},{"id":1710592,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T23:21:33.000Z","date":"2023-12-12","kind":"purchase","planned":false,"acquired":true,"shares":22327,"price":1.02,"value":22773.54,"ownership":{"direct":true},"balance_after":2302291,"source":{"system":"sec-edgar","filing":"0001209191-23-058694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123058694/doc4.xml","form_type":"4"}},{"id":1710591,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T23:21:33.000Z","date":"2023-12-12","kind":"purchase","planned":false,"acquired":true,"shares":300,"price":1,"value":300.0,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2279964,"source":{"system":"sec-edgar","filing":"0001209191-23-058694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123058694/doc4.xml","form_type":"4"}},{"id":1718834,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-07T23:30:10.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":19123,"price":1.01,"value":19314.23,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2279664,"source":{"system":"sec-edgar","filing":"0001209191-23-057799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057799/doc4.xml","form_type":"4"}},{"id":1718833,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-07T23:30:10.000Z","date":"2023-12-06","kind":"purchase","planned":false,"acquired":true,"shares":19123,"price":1.02,"value":19505.46,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2260541,"source":{"system":"sec-edgar","filing":"0001209191-23-057799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057799/doc4.xml","form_type":"4"}},{"id":1718832,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-07T23:30:10.000Z","date":"2023-12-05","kind":"purchase","planned":false,"acquired":true,"shares":19123,"price":1.01,"value":19314.23,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2241418,"source":{"system":"sec-edgar","filing":"0001209191-23-057799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057799/doc4.xml","form_type":"4"}},{"id":1725047,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T18:38:01.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":14378,"price":0.94,"value":13515.32,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.91 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2222295,"source":{"system":"sec-edgar","filing":"0001209191-23-057053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057053/doc4.xml","form_type":"4"}},{"id":1725046,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T18:38:01.000Z","date":"2023-11-30","kind":"purchase","planned":false,"acquired":true,"shares":14378,"price":0.9,"value":12940.2,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2207917,"source":{"system":"sec-edgar","filing":"0001209191-23-057053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057053/doc4.xml","form_type":"4"}},{"id":1725045,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T18:38:01.000Z","date":"2023-11-29","kind":"purchase","planned":false,"acquired":true,"shares":14378,"price":0.98,"value":14090.44,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2193539,"source":{"system":"sec-edgar","filing":"0001209191-23-057053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123057053/doc4.xml","form_type":"4"}},{"id":1754595,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer and COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-26T21:54:48.000Z","date":"2023-10-24","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the option shall vest and become exercisable on each monthly anniversary of the vesting commencement date of October 23, 2023."}],"balance_after":75000,"derivative":{"exercise_price":0.99,"expiration_date":"2033-10-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-053695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123053695/doc4.xml","form_type":"4"}},{"id":1755560,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":108787,"kind":"person","name":"Janhofer Guenter","position":1,"cik":"0001991537","reported_name":"Janhofer Guenter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-24T23:42:07.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date."}],"balance_after":300000,"derivative":{"exercise_price":0.99,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-053508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123053508/doc4.xml","form_type":"4"}},{"id":1755572,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":70810,"kind":"person","name":"Benatti Luca","position":1,"cik":"0001613842","reported_name":"Benatti Luca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-24T19:46:54.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of October 23, 2023, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date."}],"balance_after":54000,"derivative":{"exercise_price":0.99,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001209191-23-053510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613842/000120919123053510/doc4.xml","form_type":"4"}},{"id":1786661,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68487,"kind":"person","name":"Ryan Charles S.","position":1,"cik":"0001624830","reported_name":"Ryan Charles S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-06T17:43:20.000Z","date":"2023-09-01","kind":"grant","planned":false,"acquired":true,"shares":545000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest one year after the date of the grant of September 1, 2023 and the remaining shares will vest in equal monthly installments over the following three years thereafter."}],"balance_after":545000,"derivative":{"exercise_price":1.3,"expiration_date":"2033-08-31","underlying":"Common Stock","underlying_shares":545000},"source":{"system":"sec-edgar","filing":"0001209191-23-048483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624830/000120919123048483/doc4.xml","form_type":"4"}},{"id":1791692,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T22:42:15.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":41026,"price":1.32,"value":54154.32,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2179161,"source":{"system":"sec-edgar","filing":"0001209191-23-047880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123047880/doc4.xml","form_type":"4"}},{"id":1791691,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T22:42:15.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":41026,"price":1.31,"value":53744.06,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2138135,"source":{"system":"sec-edgar","filing":"0001209191-23-047880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123047880/doc4.xml","form_type":"4"}},{"id":1802865,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T22:08:21.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":24766,"price":1.29,"value":31948.14,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.28 to $1.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2097109,"source":{"system":"sec-edgar","filing":"0001209191-23-046402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123046402/doc4.xml","form_type":"4"}},{"id":1802864,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T22:08:21.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":117348,"price":1.29,"value":151378.92,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":2072343,"source":{"system":"sec-edgar","filing":"0001209191-23-046402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123046402/doc4.xml","form_type":"4"}},{"id":1802863,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T22:08:21.000Z","date":"2023-08-15","kind":"purchase","planned":false,"acquired":true,"shares":107886,"price":1.32,"value":142409.52,"ownership":{"direct":false,"nature":"By Blue Devil Trust dated 12/03/2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.34, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the \"Trust\") and holds sole voting and dispositive power with respect to the shares held of record by the Trust."}],"balance_after":1954995,"source":{"system":"sec-edgar","filing":"0001209191-23-046402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123046402/doc4.xml","form_type":"4"}},{"id":1809915,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-11T16:15:34.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":88000,"price":1.26,"value":110880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":448911,"source":{"system":"sec-edgar","filing":"0001209191-23-045432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919123045432/doc4.xml","form_type":"4"}},{"id":1811659,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-09T22:21:38.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":71762,"price":1.22,"value":87549.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":201555,"source":{"system":"sec-edgar","filing":"0001209191-23-045234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123045234/doc4.xml","form_type":"4"}},{"id":1811658,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T22:18:36.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":1.23,"value":9840.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-23-045231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123045231/doc4.xml","form_type":"4"}},{"id":1811991,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-09T18:23:31.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":80000,"price":1.24,"value":99200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":360911,"source":{"system":"sec-edgar","filing":"0001209191-23-045235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919123045235/doc4.xml","form_type":"4"}},{"id":1875876,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38030,"kind":"person","name":"Senner Christopher J.","position":1,"cik":"0001648367","reported_name":"Senner Christopher J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:53:52.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648367/000120919123032681/doc4.xml","form_type":"4"}},{"id":1876120,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35617,"kind":"person","name":"RYAN UNA S","position":1,"cik":"0001255349","reported_name":"RYAN UNA S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:50:54.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032679","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255349/000120919123032679/doc4.xml","form_type":"4"}},{"id":1875870,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:49:15.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123032677/doc4.xml","form_type":"4"}},{"id":1875869,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":38020,"kind":"person","name":"Lamond David","position":1,"cik":"0001770790","reported_name":"Lamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:47:13.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123032674/doc4.xml","form_type":"4"}},{"id":1875868,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:45:03.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123032671/doc4.xml","form_type":"4"}}],"next_cursor":"2023-05-26T21:45:03.000000Z,1875868"}